Evidence mapPaperPMID 42129307Full record

ReviewNPJ precision oncology2026

Circadian engineering of in vivo CAR T cell therapy for precision oncology.

Jhommara Bautista, Carolina E Echeverría, María Gabriella Rodríguez-Marcano, Andrés López-Cortés

Abstract readReview
In one paragraph

Review in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Metastasis in biological time.Frontiers in cell and developmental biology · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jhommara BautistaCancer Research Group (CRG), Faculty of Medicine, Universidad de Las Américas, Quito, Ecuador.
Carolina E EcheverríaDepartment of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
María Gabriella Rodríguez-MarcanoCancer Research Group (CRG), Faculty of Medicine, Universidad de Las Américas, Quito, Ecuador.
Andrés López-CortésCancer Research Group (CRG), Faculty of Medicine, Universidad de Las Américas, Quito, Ecuador. aalc84@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circadian rhythms shape antitumor immunity by regulating endocrine signaling, vascular permissiveness, leukocyte trafficking, metabolism, and suppressive features of the tumor microenvironment across the 24-h cycle. Here, we propose that biological time may represent an important design variable for CAR T-cell therapy. This concept may be particularly relevant to in vivo CAR T platforms, which could extend temporal control beyond infusion timing through repeatable induction, tunable amplitude, and reversible shutdown. We discuss evidence that CD8⁺ T-cell clocks, neuroendocrine oscillations, endothelial gatekeeping, and rhythmic tumor-microenvironment remodeling influence immune access, effector competence, exhaustion risk, and inflammatory toxicity. We further examine how viral vectors, lipid nanoparticles, and programmable control circuits might enable circadian-aware CAR installation and duty-cycling. Together, these observations support chrono-synthetic CAR T as a testable translational framework for precision immuno-oncology.

Identifiers

PMID42129307
PMCPMC13402742

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.